BioForce Nanosciences (BFNH) Stock Price, News & Analysis

Company Overview

BioForce Nanosciences, Inc. develops and markets precision instrumentation and proprietary technologies for the production and application of nanoscale materials. Its core platform employs nozzle-driven electrohydrodynamic processes to generate and deposit nanofibers, nanowires and nanoparticles with tight control over diameter, morphology and spatial arrangement. By tailoring electric field parameters and solution properties, the technology enables reproducible fabrication of structures at the nanometer scale.

The company’s product portfolio includes desktop electrospinning systems for nanofiber fabrication, electrospray modules for nanoparticle synthesis and integrated tools for bioprinting and surface patterning. In addition to equipment sales, BioForce Nanosciences offers contract research and custom development services, as well as licensing agreements for its intellectual property. Its technologies have been applied in areas such as drug delivery, tissue engineering, advanced filtration, composite materials and sensor development.

Serving academic institutions, government laboratories and corporate research centers, BioForce Nanosciences supports customers worldwide with training, application development and technical service. By combining instrumentation, service offerings and technology licensing, the company aims to accelerate the translation of nanomaterial innovations into practical solutions for life science, industrial and environmental applications.

Key Stats

• Today's Range: $2.71 to $3.40
• 50-Day Range: $1.19 to $3.40
• 52-Week Range: $0.18 to $3.40
• Volume: 10,536 shs
• Average Volume: 5,521 shs
• Market Capitalization: $114.07 million
• P/E Ratio: 340.34
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioForce Nanosciences Stock Analysis - MarketRank™

BioForce Nanosciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioForce Nanosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioForce Nanosciences is 340.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.63.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioForce Nanosciences is 340.34, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.54.

Price to Book Value per Share Ratio

BioForce Nanosciences has a P/B Ratio of 48.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of BioForce Nanosciences has been sold short.

Short Interest Ratio / Days to Cover

BioForce Nanosciences has a short interest ratio ("days to cover") of 0.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioForce Nanosciences has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioForce Nanosciences does not currently pay a dividend.

Dividend Growth

BioForce Nanosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.19

News Sentiment

BioForce Nanosciences has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BioForce Nanosciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioForce Nanosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.54% of the stock of BioForce Nanosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BioForce Nanosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 8/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BFNH
• CIK: 1310488
• Web: www.bioforceeclipse.com
• Phone: (757) 306-6090
• Fax: 757-306-6092
• Employees: 2
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 340.34
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.67%
• Return on Assets: -16.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.41
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 48.57

Miscellaneous

• Outstanding Shares: 33,549,000
• Free Float: 20,284,000
• Market Cap: $114.07 million
• Optionable: Not Optionable
• Beta: -0.52